Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-05-21
Recursion Pharmaceuticals, Inc.
Recursion uses an internal AI-enabled drug discovery and development platform plus automated labs to build its own pipeline and pharma collaborations.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof is the value unlock
This is still a proof-gated biotech, not a software annuity. The upside comes if the discovery engine turns into registrationally credible assets and richer partnership economics before cash pressure returns.

Analysis

Thesis
Recursion is a proof-gated AI biotech where the upside comes from turning proprietary data, automated labs, and owned assets into repeatable clinical wins; if REC-4881 gains a workable registrational path and one more internal program validates translation, revenue mix can shift from lumpy collaborations toward higher-value products, milestones, and royalties by 2031.
Last Economy Alignment
Cheaper cognition helps Recursion because its scarce assets are proprietary data, wet-lab throughput, and owned drug programs rather than seat software. The catch is that clinical and regulatory proof still decides whether that advantage becomes durable economics.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.4x (from 5 most recent analyses)
Reasoning
The upside is a quality shift, not just more discovery activity. If Recursion converts its platform into a registrationally credible rare-disease asset, adds one more clean internal clinical proof point, and structures partnerships to keep more downstream economics, investors can value it as a hybrid product-and-platform biotech. I still keep the rerating below premium software because biology, regulators, and trial timing remain binding constraints.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not that Recursion lacks AI tools; it is that faster discovery never turns into repeatable human proof and regulator-ready assets. If REC-4881 remains path-ambiguous, REC-1245 does not deepen confidence, or partner monetization stays episodic, the company can remain a cash-backed option story rather than compounding into a higher-quality biotech business.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They control a loop of proprietary lab data, AI tools, and internal drug programs, so cheaper AI helps them generate better shots rather than replacing the business. The risk is that biology still has to work in patients, and regulators still decide how fast that value shows up.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case